Beta Bionics shows industry-leading revenue growth and a perfect four-quarter earnings beat streak heading into a catalyst in 25 days, but quality metrics below the engine's floor, ongoing cash burn, and a price target already reached keep the risk/reward setup only marginally positive.
Thesis pillars
- Quality Below Floor Value Trap→Stable
- Strong Growth Industry Leader→Stable
- Perfect Earnings Beat Streak→Stable
- +2 more pillars — see the Why tab for full reasoning
Beta Bionics, Inc. (BBNX) Stock Analysis
Recovery setup · Catalyst-Driven edge
Healthcare · Medical Devices
Sell if holding. Engine safety override at $16.18: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10. Specifically: High short interest: 11%; Below-average business quality; Below long-term trend.
Beta Bionics is a commercial-stage medical device company that makes the iLet Bionic Pancreas, an FDA-cleared, fully closed-loop insulin delivery system for Type 1 diabetes that autonomously delivers 100% of insulin doses using CGM data from DexCom or Abbott sensors. Since its... Read more
Sell if holding. Engine safety override at $16.18: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10. Specifically: High short interest: 11%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 63. Score 5.7/10, moderate confidence.
Passes 6/9 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 22d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: speculative.
About Beta Bionics, Inc.
About Beta Bionics, Inc.
Beta Bionics has grown its installed base of iLet Bionic Pancreas devices to 35,011 units as of December 31, 2025, roughly two and a half years after the FDA cleared the fully closed-loop insulin-delivery system in May 2023 for people with Type 1 diabetes aged six and older. The iLet is the company's sole commercial product and currently generates all of its revenue, sold exclusively in the United States through a direct commercial organization and a network of independent distributors.
Beta Bionics sells the iLet directly to patients and providers, billing third-party payors under two reimbursement models: the traditional durable medical equipment (DME) channel, which requires a large upfront payment and limits replacement to once every four years, and a newer pharmacy benefit plan (PBP) channel that spreads costs on a pay-as-you-go basis and is intended to generate more recurring revenue over a device's life. Distribution is concentrated: the company's top four DME distributors accounted for approximately 52% of total sales in 2025, a concentration Beta Bionics is trying to dilute by expanding direct payor contracts and the PBP channel. The iLet's core technology depends on continuous glucose monitor data from DexCom and Abbott sensors under commercial integration agreements, and Beta Bionics manufactures the device and its insulin cartridges at a single facility in Irvine, California, sourcing certain components from qualified third-party suppliers under a multi-sourcing strategy.
Show full overview
Beta Bionics's entire revenue base rests on one device: the 10-K states the company currently relies on sales of the iLet and its single-use products to generate all of its revenue, and that this exposure extends to the CGM sensors the iLet depends on, since its DexCom and Abbott integration agreements could be terminated on relatively short notice, with or without cause. A termination of either CGM partnership, a regulatory action affecting compatible sensors, or a shift in the DME/PBP reimbursement mix could each hit the same single revenue stream, with no second commercial product, such as the tubeless Mint patch pump targeted for a 2027 launch, yet available to diversify that risk.
See also: Healthcare · Medical Devices
From Beta Bionics, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductiLet10-K Item 1A: 'We currently rely on sales of our iLet and related single-use products to generate all of our revenue'
- HIGHCustomertop four DME distributors52%10-K Item 1A: 'our top four DME distributors represented approximately 52% of our total sales'
- MEDIUMcounterpartyDexCom, Abbott10-K Item 1A: 'sales of any of our current or future insulin delivery device products with CGM integration are subject to the continuation of our applicable agreements with DexCom, Abbott, or other third parties'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Unprofitable operations — net margin -60.3%. Quality floor flags this regardless of sector context.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $16.18: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10. Specifically: High short interest: 11%; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 63. Prior stop was $15.05. Score 5.7/10, moderate confidence.
Take-profit target: $16.69 (+3.2% upside). Prior stop was $15.05. Stop-loss: $15.05.
Concentration risk — Product: iLet; Concentration risk — Customer: top four DME distributors (52.0%); Quality below floor (2.9 < 4.0).
Beta Bionics, Inc. trades at a P/E of N/A (forward -7.0). TrendMatrix value score: 5.3/10. Verdict: Sell.
18 analysts cover BBNX with a consensus score of 4.1/5. Average price target: $19.
What does Beta Bionics, Inc. do?Beta Bionics is a commercial-stage medical device company that makes the iLet Bionic Pancreas, an FDA-cleared, fully...
Beta Bionics is a commercial-stage medical device company that makes the iLet Bionic Pancreas, an FDA-cleared, fully closed-loop insulin delivery system for Type 1 diabetes that autonomously delivers 100% of insulin doses using CGM data from DexCom or Abbott sensors. Since its May 2023 U.S. launch, the installed base has grown to 35,011 iLets as of December 31, 2025, and the iLet currently generates all of the company's revenue.